Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | CETP | P11597 | 1/20 | 0.54 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.54 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.54 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1030263 | 0.84 | LMNA (0.74) | LMNAKDM4EALOX12CETPPDK1 | |
| SCHEMBL2952213 | 0.81 | CETP (0.45) | LMNAKDM4EALOX12CETPPDK1 | |
| SCHEMBL2543800 | 0.81 | BRD4 (0.57) | LMNAKDM4EL3MBTL1ALDH1A1TSHR | |
| SCHEMBL2062142 | 0.81 | LMNA (0.45) | LMNAKDM4EALOX12PDK1PDK2 | |
| SCHEMBL5706504 | 0.80 | CETP (0.71) | LMNAKDM4EALOX12CETPPDK1 | |
| SCHEMBL7721814 | 0.79 | LMNA (0.55) | LMNAKDM4EALOX12CETPPDK1 | |
| SCHEMBL383654 | 0.78 | CNR2 (0.48) | LMNAKDM4EPDK1PDK2PDK3 | |
| SCHEMBL2087952 | 0.76 | CETP (0.67) | LMNAKDM4EALOX12CETPPDK1 | |
| SCHEMBL6348512 | 0.75 | PDK1 (0.72) | LMNAKDM4EALOX12PDK1PDK2 | |
| SCHEMBL8183410 | 0.74 | L3MBTL1 (0.53) | LMNAKDM4EALOX12CETPPDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1330456-B8 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2012-02-08 | — | — | EP | disclosed |
| EP-1330456-B9 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-1330456-B1 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2011-06-15 | — | — | EP | disclosed |
| US-7115619-B2 | N8, N13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-10-03 | — | — | US | disclosed |
| US-20040063739-A1 | N8, n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-04-01 | — | — | US | disclosed |
| EP-1330456-A2 | N8,N13 -DISUBSTITUTED QUINO 4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002030932-A2 | N8,N13-DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063739-A1 | N8, n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents | TERT, MKI67, NQO2 | LMNA 450/4885KDM4E 322/4885ALOX12 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.